Thromboxane A2 synthetase inhibitor (OKY-046) improves abnormal mucociliary transport in asthmatic patients.
The effect of a thromboxane A2 synthetase inhibitor (OKY-046, 400 mg po/day) on mucociliary transport was investigated in 19 asthmatic patients. The nasal clearance time, as measured by the saccharin test, was prolonged in asthmatics (60.2 +/- 8.4 SE min) compared with normal controls (15.1 +/- 3.4 SE min). Within 4 weeks after OKY-046 administration, the nasal clearance time had improved (27.4 +/- 4.4 SE min, P less than .01) and the amount of sputum had decreased 30% (P less than .01). These results indicate that thromboxane A2 plays an important role in mucociliary transport in patients with asthma.
Kurashima
K
K
Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
Ogawa
H
H
Ohka
T
T
Fujimura
M
M
Matsuda
T
T
D000368:Aged; D001249:Asthma / Q000188:drug therapy / Q000503:physiopathology*; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D008689:Methacrylates / Q000627:therapeutic use*; D008875:Middle Aged; D009079:Mucociliary Clearance / Q000187:drug effects*; D009297:Nasal Mucosa / Q000503:physiopathology; D013183:Sputum; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D008689:Methacrylates; D013930:Thromboxane-A Synthase; C034364:ozagrel